Literature DB >> 29610122

In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Sotirios Tsimikas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29610122      PMCID： PMC5928428          DOI： 10.1194/jlr.C085639

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  39 in total

1.  Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes.

Authors:  Ayşem Kaya; Altan Onat; Hüsniye Yüksel; Günay Can; Murat Yüksel; Evin Ademoğlu
Journal:  Postgrad Med       Date:  2017-06-22       Impact factor: 3.840

2.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

3.  Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction.

Authors:  Andrew P DeFilippis; Ilya Chernyavskiy; Alok R Amraotkar; Patrick J Trainor; Shalin Kothari; Imtiaz Ismail; Charles W Hargis; Frederick K Korley; Gregor Leibundgut; Sotirios Tsimikas; Shesh N Rai; Aruni Bhatnagar
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

4.  LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.

Authors:  Di-Li-Da-Er Mu-Han-Ha-Li 迪丽达尔 木汗哈力; Tian-Yu Zhai 翟天羽; Yan Ling 凌雁; Xin Gao 高鑫
Journal:  J Lipid Res       Date:  2018-03-06       Impact factor: 5.922

5.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

6.  Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects.

Authors:  H Vaverková; D Karásek; M Halenka; L Cibíčková; V Kubíčková
Journal:  Physiol Res       Date:  2017-04-05       Impact factor: 1.881

7.  Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.

Authors:  Andreas Festa; Ken Williams; Russell P Tracy; Lynne E Wagenknecht; Steven M Haffner
Journal:  Circulation       Date:  2006-04-03       Impact factor: 29.690

8.  Lipoprotein (a) is associated with basal insulin levels in patients with type 2 Diabetes Mellitus.

Authors:  Syed Shahid Habib; Muhammad Aslam; Syed Fayaz Ahmad Shah; Abdul Khaliq Naveed
Journal:  Arq Bras Cardiol       Date:  2009-07       Impact factor: 2.000

9.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

10.  Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR.

Authors:  Matthew B Lanktree; Chandheeb Rajakumar; J Howard Brunt; Marlys L Koschinsky; Philip W Connelly; Robert A Hegele
Journal:  J Lipid Res       Date:  2008-12-05       Impact factor: 5.922
View more
  6 in total

Review 1.  Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.

Authors:  Nishant P Shah; Neha J Pajidipati; Robert W McGarrah; Ann Marie Navar; Sreekanth Vemulapalli; Michael A Blazing; Svati H Shah; Adrian F Hernandez; Manesh R Patel
Journal:  Am J Cardiol       Date:  2020-04-07       Impact factor: 2.778

2.  Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes.

Authors:  Angelo Silverio; Francesco Paolo Cancro; Marco Di Maio; Michele Bellino; Luca Esposito; Mario Centore; Albino Carrizzo; Paola Di Pietro; Anna Borrelli; Giuseppe De Luca; Carmine Vecchione; Gennaro Galasso
Journal:  J Thromb Thrombolysis       Date:  2022-09-20       Impact factor: 5.221

3.  Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry.

Authors:  Benjamin A Satterfield; Ozan Dikilitas; Maya S Safarova; Shoa L Clarke; Catherine Tcheandjieu; Xiang Zhu; Lisa Bastarache; Eric B Larson; Anne E Justice; Ning Shang; Elisabeth A Rosenthal; Amy Sanghavi Shah; Bahram Namjou-Khales; Elaine M Urbina; Wei-Qi Wei; QiPing Feng; Gail P Jarvik; Scott J Hebbring; Mariza de Andrade; Teri A Manolio; Themistocles L Assimes; Iftikhar J Kullo
Journal:  Circ Genom Precis Med       Date:  2021-07-20

Review 4.  Lipoprotein(a): An underrecognized genetic risk factor for malignant coronary artery disease in young Indians.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-05-02

Review 5.  Conceptualization of Heterogeneity of Chronic Diseases and Atherosclerosis as a Pathway to Precision Medicine: Endophenotype, Endotype, and Residual Cardiovascular Risk.

Authors:  Vadim V Genkel; Igor I Shaposhnik
Journal:  Int J Chronic Dis       Date:  2020-02-12

Review 6.  Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida
Journal:  J Atheroscler Thromb       Date:  2019-09-20       Impact factor: 4.928
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.